$1.80
−11.33%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.86
From 52W high−98.51%
Volume215375.00
Market cap$3.42M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.86
From 52W high
−98.51%
Volume
215375.00
Market cap
$3.42M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
18.6
MomentumView details →
1D Return
−11.33%
YTD Return
−97.58%
SummaryUpdated Jun 1, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) is a clinical-stage biotechnology company that went public in November 2024. Founded as a biotech venture focused on developing innovative cancer treatments, the company specializes in advancing non-invasive therapeutic solutions for skin cancer. As a recently public entity, Medicus represents an early-stage biotech firm transitioning from private development to public markets while pursuing clinical trials for its novel therapeutic candidates.
Similar companies
Latest newsMore news →
Medicus Pharma announced that its wholly owned subsidiary Skinject entered into a non-binding letter of intent with an undisclosed SPAC for a proposed business combination involving Skinject.7h agoNASDAQ, INC. confirmed that Medicus Pharma Ltd. regained compliance with its minimum bid price requirement and closed the matter.9d agoMedicus Pharma provided a shareholder update marking its third anniversary and outlining its progress and potential path to long-term value.27d ago